Roch-Philippe Charles becomes new CSO of the SAKK

The SAKK Board and Executive Committee are welcoming Roch-Philippe Charles as the new Chief Scientific Officer (CSO) on November 1, 2022.

Roch-Philippe Charles becomes new CSO of the SAKK

The SAKK Board and Executive Committee are welcoming Roch-Philippe Charles as the new Chief Scientific Officer (CSO) on November 1, 2022.

Charles was most recently Medical Affairs Manager at InnoMedica Holding AG in Bern. He previously taught for seven years as an assistant professor at the University of Bern Faculty of Medicine and as a project head at NCCR-TransCure (Institute of Biochemistry and Molecular Medicine, University of Bern). Here, he did research to translate novel approaches for cancer therapy that were developed on lab benches into treatments in mice and therapies in humans.

He obtained his doctorate in biology from the University of Lausanne (UNIL) and carried out post-doctorate research at the Helen Diller Comprehensive Cancer Center at the University of California in San Francisco (UCSF).

What Charles is most looking forward to as CSO at SAKK is contributing within the Group to the further development of what is a fundamental organization for oncological research in Switzerland, and thereby to clinical cancer research.

 

All News